<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 2 Study of Ruxolitinib (JAK1/2 Inhibitor) in Combination With Corticosteroids<br> for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-showx2" href="images/study-rationale/Incyte ASCO 2017 TS mockup INC-1170c REACH 1 (Steroid-Refractory Acute GVHD).jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 primary-objectives-nav1 bg-blue">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav1">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav1">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top1" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content1">
				<!-- section 1 -->
				<div id="po1"></div>
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po1">
						<div class="absolute-cen">
						<h3>Primary objective:</h3>
						<ul>
							<li>Assess efficacy of ruxolitinib in combination with corticosteroids in subjects with Grade II–IV steroid-refractory acute GVHD</li>
						</ul>
						<br>
						<h3 id="po1">secondary objectives:</h3>
							<ul>
								<li>Assess additional response and longer-term efficacy outcomes in the study population</li>
								<li>Assess the incidence and severity of adverse events and serious adverse events</li>
								<li>Evaluate the pharmacokinetics of ruxolitinib when administered in combination with corticosteroids</li>
							</ul>
						<br>
						<h3>Exploratory objective:</h3>
						<ul id="po1">
							<li>Evaluate pre- and post-treatment changes in biomarkers, including (but not limited to) tumor necrosis factor receptor 1, ST2, and regenerating islet-derived 3-alpha</li>
						</ul>
						</div>
						<div id="po1"></div>
					</div>
					<div id="po1"></div>

					<!-- section 2 -->
					<div id="sd1" class="target">
						<div class="absolute-cen">
						<h3>Study Design</h3>
						<img class="img-responsive" src="images/study-design/study-design1.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
						</div>
					</div>
					<!-- section 3 -->
					<div id="kiec1" class="target2">
						<div class="absolute-cen">
						<h3 >Key inclusion criteria:</h3>
						<ul>
							<li>Age ≥12 years</li>
							<li>Have undergone first allo-HSCT from any donor source and donor type</li>
							<li>Grade II–IV steroid-refractory acute GVHD</li>
							<li>Evidence of myeloid engraftment</li>
						</ul>
						<br>
						<h3>Key exclusion criteria:</h3>
						<ul>
							<li>Has received >1 allo-HSCT</li>
							<li>Has received >1 systemic treatment in addition to corticosteroids for acute GVHD</li>
							<li>Previously received Janus kinase inhibitor therapy after allo-HSCT for any indication</li>
							<li>Presence of active uncontrolled infection</li>
							<li>Severe organ dysfunction unrelated to underlying GVHD</li>
						</ul>
						</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm1" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
		<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>allo-HSCT = allogeneic hematopoietic stem cell transplantation, DOR = duration of response, FFS = failure-free survival, GVHD = graft-versus-host disease,
NRM = nonrelapse mortality, ORR = overall response rate, OS = overall survival, REACH = Ruxolitinib in patiEnts with refrACtory graft versus Host disease
after allogeneic stem cell transplantation</p>
</div>